Brand-name drug · GLP-1 receptor agonist

Foundayo (orforglipron)

From the FDA label, read Published by PepVault

Foundayo is orforglipron, a once-daily tablet from Eli Lilly that can be taken with or without food.

FDA approved it, together with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off in adults with obesity, or with overweight and at least one weight-related condition.

Active ingredient
Orforglipron
Maker
Eli Lilly
Class
GLP-1 receptor agonist
FDA application
NDA 220934, first approved 2026

What FDA approved it for

Weight is its one approved use. The label advises against taking it with another GLP-1 medicine.

From the label: 2.1 Recommended Dosage and Administration; 1 Indications and Usage.

How it is supplied

Foundayo’s forms and the doses each one gives, as the label lists them
FormDoses
Tablet0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg

From the label: 3 Dosage Forms and Strengths.

The label’s dosing schedule

This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.

Foundayo, once a day

0.8 mg2.5 mg5.5 mg9 mgif needed14.5 mgif needed17.2 mgif needed
Foundayo’s steps as the label lays them out, lowest to highest; each bar’s height is its dose against the top dose. A dashed bar is a step the label allows only if more is needed.
Foundayo, once a day: the steps on the label. Highest dose: 17.2 mg a day.
DoseWhen, on the label
0.8 mg a dayAt least 30 days
2.5 mg a dayAt least 30 days
5.5 mg a dayAt least 30 days
9 mg a dayAfter at least 30 days, by response and tolerability
14.5 mg a dayAfter at least 30 days, by response and tolerability
17.2 mg a dayThe maximum

The first three steps, 0.8 mg, 2.5 mg and 5.5 mg, each last at least 30 days and are there to lower the chance of stomach side effects. Beyond 5.5 mg, each higher level follows only if the response and tolerability call for it.

From the label: 2.1 Recommended Dosage and Administration.

How it’s taken

One tablet a day, swallowed whole, with no breaking, crushing or chewing and never more than one in a day. Unlike the semaglutide tablets, the label sets no empty-stomach rule: food is fine.

Some other medicines change how much orforglipron the body keeps. With a strong CYP3A4 inhibitor the label caps Foundayo at 9 mg a day, and it asks to avoid strong CYP3A4 inducers altogether.

From the label: 2.1 Recommended Dosage and Administration; 2.2 Dosage Modification for Concomitant Use with CYP3A4 Inhibitors and CYP3A4 Inducers.

A smiling woman in a dark training top in her kitchen, holding a glass of water

PepVault for iPhone

Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

If a dose is missed

A missed Foundayo tablet is taken as soon as it’s remembered, without doubling the next one.

After 7 or more missed days in a row, the label restarts the climb at a lower dose.

From the label: 2.3 Recommendations Regarding Missed Dose.

Storage

Foundayo needs no fridge: it is stored at room temperature, 68°F to 77°F, with short spells between 59°F and 86°F allowed.

From the label: 16.2 Storage and Handling.

Side effects and warnings

Adverse reactions in adults on Foundayo and more often than on placebo, two weight trials (first ten rows). Percent of people.
ReactionPlacebo5.5 mg9 mg17.2 mg
Nausea10263435
Constipation9202724
Diarrhea11212325
Vomiting4132124
Dyspepsia4121613
Abdominal pain7131414
Headache7899
Abdominal distension3798
Fatigue4679
Eructation (burping)1688

Nausea led, reported by 35% on 17.2 mg against 10% on placebo; constipation, diarrhea and vomiting each reached about a quarter of people on the higher doses.

The boxed warning

Boxed warning: “RISK OF THYROID C-CELL TUMORS”Foundayo’s boxed warning on thyroid C-cell tumors reads differently from the injected GLP-1s. Medicines that act on the GLP-1 receptor in rats and mice cause these tumors in rodents, but orforglipron doesn’t act in rats or mice and didn’t cause tumors there; it does act on the human receptor, and whether the rodent finding matters for people is unknown. People with a personal or family history of medullary thyroid carcinoma, or with MEN 2, should not use it.

The other warnings

Its other warnings: pancreatitis, severe stomach effects, kidney injury from fluid loss, low blood sugar, allergic reactions, diabetic eye changes in type 2 diabetes, gallbladder disease and aspiration under anesthesia.

From the label: 6.1 Clinical Trials Experience; Boxed Warning; 5 Warnings and Precautions.

What else we have on orforglipron

Brand against brand

Questions about Foundayo

What is the starting dose of Foundayo?

The label starts at 0.8 mg once a day for at least 30 days, then 2.5 mg, then 5.5 mg, each for at least 30 days. A prescriber sets the schedule.

What is the maximum dose of Foundayo?

17.2 mg once a day. With a strong CYP3A4 inhibitor, the label’s cap is 9 mg a day.

Does Foundayo have to be taken on an empty stomach?

No. The label says to take it once a day with or without food, swallowed whole.

What if I miss a Foundayo dose?

Take it as soon as possible and don’t double the next one. After 7 or more missed days in a row, the label restarts the climb at a lower dose.

What is Foundayo approved for?

Reducing excess weight and keeping it off, with diet and activity, in adults with obesity or with overweight and a weight-related condition.

Sources

PepVault is not affiliated with Eli Lilly. Foundayo is a trademark of its owner.

PepVault for iPhone

Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo